Read about CHRETO ApS

Digital media

ING/
Vi har kvalificeret din tech-viden siden 1892
ING/Version2
Den skarpeste dækning af de vigtigste it-nyheder
ING/Radar
Fordi tech er politisk
ING/Pro
Nicheviden for professionelle
- ING/BuildingTech
  Byggeri, renovering og vedligehold
- ING/CareTech
  Velfærdsteknologi og hjælpemidler
- ING/ComplianceTech
  GDPR og compliance
- ING/DataTech
  Analytics og data
- ING/DigiTech
  Offentlig digitalisering og IT-projekter
- ING/GridTech
  Energi og elektrificering
- ING/MobilityTech
  Transport og trafik
- ING/WasteTech
  Affald og genanvendelse
- ING/WaterTech
  Teknologi og vandets kredsløb
Transformator
Ugentlig podcast med teknologiske nyheder og tendenser

Print media

Commercial

About CHRETO ApS

CHRETO is developing a cost effective and flexible, disruptive single-use platform technology for affinity purification to be used in the biopharmaceutical industry.

Our vision is that the CHRETO technology™ will radically improve the process efficiency of downstream processing of large biomolecules. We believe that CHRETO’s Protein Purification Technology will bring a true revolution to bio-manufacturing, which has been sought by the industry for decades.

Our goals are to have the first product on market in 2018 and to position CHRETO as the preferred purification technology for monoclonal antibodies (mAb) and intravenous immunoglobulin (IVIG) going forward.